Neil Skolnik, MD
Family Medicine · Jenkintown, PANPI 1275564619
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $550,267 of the $904,281 with a category attached, or 60.9%. 25 manufacturers reported payments, led by AstraZeneca at 30.8% of the total. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 794 payments — averaging $1138.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$278K
- GSK$161K
- Lilly USA, LLC$100K
- Boehringer Ingelheim$75K
- Eli Lilly$70K
- Novo Nordisk$41K
- plus $179K from 19 others
Across 4 payments — averaging $2123.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- Sanofi-aventis U.S. LLC$4K
What the payments were for
- Consulting fees$550,26761%
- Speaking & faculty fees$270,84130%
- Travel & lodging$71,6498%
- Food & beverage$11,3351%
- Education$1300%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 265 | $278,309 |
| GSK | 121 | $161,234 |
| Lilly USA, LLC | 93 | $99,795 |
| Boehringer Ingelheim | 70 | $74,831 |
| Eli Lilly | 87 | $70,358 |
| Novo Nordisk | 25 | $40,885 |
| Bayer | 29 | $30,467 |
| Astrazeneca AB | 10 | $25,309 |
| Sanofi-aventis U.S. LLC | 18 | $25,214 |
| Sanofi | 12 | $20,516 |
| Astrazeneca UK Limited | 10 | $14,406 |
| Teva Pharmaceuticals USA, Inc. | 4 | $13,855 |
| Astellas Pharma US Inc | 6 | $9,100 |
| Insulet Corporation | 14 | $7,612 |
| Embecta Corp. | 3 | $5,647 |
| Abbott | 5 | $4,963 |
| Merck | 6 | $4,634 |
| Sanofi Pasteur Inc. | 4 | $4,416 |
| Viiv Healthcare Company | 2 | $4,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,640 |
| Novartis | 2 | $2,572 |
| Azurity Pharmaceuticals, Inc. | 2 | $1,688 |
| Boehringer Ingelheim International GmbH | 1 | $975 |
| Regeneron Healthcare Solutions, Inc. | 3 | $798 |
| Mannkind Corporation | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$73,242
- ZEPBOUND$68,088
- TRELEGY ELLIPTA$66,707
- JARDIANCE$37,718
- BREZTRI$33,827
- SOLIQUA 100/33$20,774
- FARXIGA$20,679
- Kerendia$15,940
- Non-Covered$13,125
- LOKELMA$12,943
- NUCALA$12,900
- STIOLTO RESPIMAT$10,210
- BREZTRI AEROSPHERE$10,200
- Veozah$9,063
- Wegovy$8,927
- ProAir Digihaler$7,680
- Omnipod$7,387
- FASENRA$6,873
- BYDUREON$5,069
- Afinion 2$4,888
How this compares
$904,281 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 61 | $29,112 |
| EliquisApixaban | 109 | $28,671 |
| JardianceEmpagliflozin | 41 | $25,402 |
| XareltoRivaroxaban | 49 | $19,179 |
| JanuviaSitagliptin Phosphate | 51 | $12,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,801 |
| Victoza 3-PakLiraglutide | 11 | $8,523 |
| QuliptaAtogepant | 15 | $7,762 |
| ElmironPentosan Polysulfate Sodium | 17 | $7,319 |
| NeuproRotigotine | 22 | $5,256 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $4,987 |
| Atorvastatin Calcium | 230 | $3,672 |
| Bumetanide | 33 | $2,851 |
| Novolog FlexpenInsulin Aspart | 12 | $2,817 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $278,309 | $29,11261 claims |
| Boehringer IngelheimJardiance, Pradaxa | $74,831 | $27,59861 claims |
| MerckJanuvia | $4,634 | $12,86551 claims |
| GSKTrelegy Ellipta | $161,234 | $9,80114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Jenkintown
- John RussellJenkintown$82K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.